Price T Rowe Associates Inc. MD reduced its stake in shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) by 9.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 142,427 shares of the company’s stock after selling 14,848 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.34% of Syros Pharmaceuticals worth $1,319,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of SYRS. Bank of Montreal Can increased its stake in shares of Syros Pharmaceuticals by 11,319.2% during the second quarter. Bank of Montreal Can now owns 2,969 shares of the company’s stock worth $27,000 after acquiring an additional 2,943 shares during the period. A.R.T. Advisors LLC acquired a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at approximately $119,000. Algert Global LLC acquired a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at approximately $166,000. Bank of New York Mellon Corp boosted its holdings in shares of Syros Pharmaceuticals by 27.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 105,908 shares of the company’s stock valued at $981,000 after buying an additional 22,658 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Syros Pharmaceuticals by 80.7% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 203,968 shares of the company’s stock valued at $1,889,000 after buying an additional 91,081 shares during the last quarter. 82.08% of the stock is currently owned by institutional investors.
Several equities research analysts have recently commented on the company. BidaskClub downgraded Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 4th. Zacks Investment Research upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 28th. ValuEngine cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, October 7th. Finally, Roth Capital assumed coverage on Syros Pharmaceuticals in a research report on Friday, July 12th. They set a “buy” rating and a $17.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. Syros Pharmaceuticals presently has an average rating of “Hold” and an average price target of $16.03.
Syros Pharmaceuticals stock opened at $8.79 on Friday. The stock’s 50 day moving average is $10.28 and its 200 day moving average is $8.25. The company has a quick ratio of 8.11, a current ratio of 8.11 and a debt-to-equity ratio of 0.15. Syros Pharmaceuticals Inc has a one year low of $5.17 and a one year high of $11.93.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Thursday, August 1st. The company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.06). Syros Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 3,137.55%. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.42 million. On average, equities research analysts forecast that Syros Pharmaceuticals Inc will post -1.94 EPS for the current fiscal year.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Recommended Story: Average Daily Trade Volume Explained
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.